CD109 (E123) Antibodies

The CD109 antigen is a monomeric glycosyl phosphatidylinositol (GPI)-linked glycoprotein of 170 kDa. It is a novel member of the α2 macroglobulin (α2M) / C3, C4, C5 family of thioestercontaining proteins. CD109 is found on vascular endothelial cells, some epithelial cells, activated T-cells, activated platelets, leukemic megakaryoblasts and a subset of bone marrow CD34+ cells. It is not expressed on fresh peripheral blood lymphocytes (PBL). Poorly differentiated (CD34+, TdT+, CD7+) T-acute leukemias and rare cases of chronic myeloid leukemia in megakaryoblast crisis express the CD109 antigen. Furthermore, megakaryoblastoid cell lines (MO7e, MOLM-1) are CD109+. The CD109 antigen may represent a very early marker for hematopoietic cells committed to the megakaryocyte lineage. In contrast, the adult bone marrow CD34+ CD109+ subset identifies the most primitive hematopoietic stem cells capable of long-term culture and lymphoid progenitors of the B-cell lineage.


Clone: 8A3 Isotype: IgG2a Mouse

Explore CD109 (E123) Antibodies

Content and Resources

Immunophenotyping reference table - For haematopoietic malignancies Poster - Immunophenotyping reference table - For haematopoietic malignancies
How do I preserve sensitivity? Poster - How to preserve sensitivity
IVDR: a new era for In-Vitro Diagnostic Medical Devices BEC Marseille IVDR team, in the framework of the IVDR Global program, has established and deployed a robust project plan to fulfill IVDR requirements of more than 230 IVD CE marked products for May 2022
Mesenchymal Stem Cells (MSC) - Conjugated Antibody Portfolio CD133-APC completed conjugated antibody portfolio for basic mesenchymal progenitor cells studies